Characteristics, main indication for rituximab biosimilar, regimen and response to treatment of 32 enrolled patients
| Number | Previous therapy (other than steroids and antimalarial) | Specific organ involvement | Baseline prednisolone (mg/day) | RTX biosimilar regimen (mg) × infusion(s) | Concomitant therapy (other than steroids and antimalarial) | Prednisolone at 6 months (mg/day) | Response by organ involvement |
| 1 | IVCY | Seizure* | 60 | 1000×2 | IVCY | 15 | Y |
| 2 | IVCY | Transverse myelitis* | 60 | 1000×2 | AZA | 7.5 | Y |
| 3 | MTX, TAC, MMF, IVIG | Chronic inflammatory demyelinating polyneuropathy* | 30 | 1000×2 | LEF, TAC, MMF | 30 | Y |
| 4 | MMF, CY | Small fibre neuropathy* | 15 | 500×2 | CY | 10 | Y |
| 5 | IVCY, IVIG, PLEX | Acute confusional state, lupus nephritis* | 60 | 1000×1 | AZA | 17.5 | Y, Y |
| 6 | IVCY | Acute confusional state, lupus nephritis, thrombocytopaenia* | 75 | 1000×1 | AZA | 10 | Y, Y, Y |
| 7 | AZA, IVCY | Lupus headache* | 20 | 1000×2 | AZA, CYA | 10 | Y |
| 8 | IVCY, PLEX | Gastrointestinal vasculitis*, lupus nephritis (class III) | 50 | 1000×1 | MMF, IVCY | 30 | Y, Y |
| 9 | MMF, CY | Cutaneous vasculitis* | 15 | 1000×2 | MMF, AZA | 15 | Y |
| 10 | CYA, IVCY | Arthritis* | 30 | 1000×2 | CYA, MTX | 10 | Y |
| 11 | MTX | Arthritis* | 17.5 | 500×2 | MTX, MMF | 10 | Y |
| 12 | MTX | Arthritis* | 5 | 500×2 | MTX, MMF | 10 | Y |
| 13 | MMF, IVCY | Lupus nephritis* | 25 | 500×2 | MMF, TAC | 10 | Y |
| 14 | IVCY, PLEX | Lupus nephritis* | 40 | 500×2 | MMF | 10 | Y |
| 15 | CYA, MMF, IVCY | Lupus nephritis (class IV)* | 20 | 1000×2 | CYA, MMF | 10 | Y |
| 16 | MTX, MMF | Lupus nephritis* | 1.5 | 1000×2 | MTX, MMF | 0.5 | N |
| 17 | CYA, MMF | Lupus nephritis (class IV+V)* | 10 | 1000×2 | CYA, MMF | 7.5 | N |
| 18 | MTX, MMF | Lupus nephritis* | 5 | 1000×2 | MTX, CYA, MMF | 5 | N |
| 19 | MMF, IVCY | Lupus nephritis (class III)* | 75 | 500×2 | MMF, IVCY | 20 | Y |
| 20 | AZA, MMF | Lupus nephritis*, thrombocytopaenia | 40 | 1000×1 | AZA, MMF | 7.5 | Y, Y |
| 21 | IVCY | Lupus nephritis*, thrombocytopaenia | 60 | 500×3 | None (expired from infection) | – | N, N |
| 22 | MMF, IVIG | Lupus nephritis (class III+V)*, thrombocytopaenia | 30 | 1000×1 | MMF | 20 | N, Y |
| 23 | MMF | Photosensitive lupus rash* | 15 | 500×2 | MMF | 10 | Y |
| 24 | AZA, CYA, MMF | Thrombocytopaenia* | 12.5 | 500×2 | AZA, CYA, MMF | 7.5 | N |
| 25 | MMF | Thrombocytopaenia* | 20 | 500×2, 1000×1 | MMF, IVIG | 10 | N |
| 26 | AZA, CYA | Thrombocytopaenia* | 15 | 1000×2 | AZA, CYA | 5 | Y |
| 27 | AZA, CYA | Thrombocytopaenia* | 15 | 1000×2 | AZA, CYA | 2.5 | Y |
| 28 | AZA, CYA, MMF | Thrombocytopaenia* | 12.5 | 500×2 | AZA, CYA, MMF | 10 | N |
| 29 | AZA, TAC | Leucopenia* | 12.5 | 500×2 | AZA, TAC | 7.5 | N |
| 30 | AZA | Leucopenia* | 40 | 1000×2 | AZA | 25 | N |
| 31 | AZA, MMF | Leucopenia* | 5 | 500×1 | AZA, MMF | 5 | N |
| 32 | AZA | Coagulation factor inhibitor* | 75 | 500×4 | MMF | 30 | Y |
*Main indication for rituximab biosimilar infusion.
AZA, azathioprine; CY, oral cyclophosphamide; CYA, ciclosporin A; IVCY, intravenous cyclophosphamide; IVIG, intravenous immunoglobulin; LEF, leflunomide; MMF, mycophenolate mofetil; MTX, methotrexate; N, no; PLEX, plasma exchange; RTX, rituximab; TAC, tacrolimus; Y, yes.